TY - JOUR
T1 - Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer
T2 - Subgroup Analysis of CheckMate 141
AU - Gillison, Maura L.
AU - Blumenschein, George
AU - Fayette, Jerome
AU - Guigay, Joel
AU - Dimitrios Colevas, A.
AU - Licitra, Lisa
AU - Harrington, Kevin J.
AU - Kasper, Stefan
AU - Vokes, Everett E.
AU - Even, Caroline
AU - Worden, Francis
AU - Saba, Nabil F.
AU - Docampo, Lara Carmen Iglesias
AU - Haddad, Robert
AU - Rordorf, Tamara
AU - Kiyota, Naomi
AU - Tahara, Makoto
AU - Jayaprakash, Vijayvel
AU - Wei, Li
AU - Ferris, Robert L.
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press.
PY - 2022/2
Y1 - 2022/2
N2 - In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator’s choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.
AB - In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator’s choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.
KW - clinical trial
KW - immunotherapy
KW - nivolumab
KW - squamous cell carcinoma of head and neck
UR - http://www.scopus.com/inward/record.url?scp=85131202545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131202545&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyab036
DO - 10.1093/oncolo/oyab036
M3 - Article
C2 - 35641218
AN - SCOPUS:85131202545
SN - 1083-7159
VL - 27
SP - E194-E198
JO - Oncologist
JF - Oncologist
IS - 2
ER -